483
Krystal Biotech, Inc.FDA 483 - Krystal Biotech, Inc. - January 30, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Krystal Biotech, Inc. in Pittsburgh, PA, revealed significant deficiencies in their quality system. The firm failed to thoroughly investigate approximately 30 deviations related to drug substance manufacturing for VYJUVEK, leading to the release of commercial batches without adequate corrective actions. Additionally, the company did not establish the reliability of supplier Certificates of Analysis for critical components.
Open in Dashboard
ID · 6052640f-1207-4f00-b797-0b772a72f82f